Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 286.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 3.00 (1.045%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 286.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK shareholder meetings calendar - next 7 days

Wed, 20th Apr 2022 16:05

Thursday 21 April 
Alliance Trust PLCAGM
Ibstock PLCAGM
Journeo PLCAGM
Relx PLCAGM
STV Group PLCAGM
Ruffer Investment Co LtdEGM re share issue
Friday 22 April 
Bellevue Healthcare Trust PLCAGM
Faron Pharmaceuticals LtdAGM
Murray International Trust PLCAGM
Monday 25 April 
Belluscura PLCAGM
Capital Gearing Trust PLCGM re non pre-emptive share issue
Cloudbreak Discovery PLCGM re Crescita equity drawdown agreement
Hikma Pharmaceuticals PLCAGM
JPMorgan US Smaller Cos Investment Trust PLCAGM
Polymetal International PLCAGM
Symphony International Holdings LtdAGM
Tuesday 26 April 
Aquis Exchange PLCAGM
Elementis PLCAGM
GlobalData PLCAGM
Oriole Resources PLCAGM
RPS Group PLCAGM
SigmaRoc PLCAGM
Taylor Wimpey PLCAGM
Tissue Regenix Group PLCAGM
Wednesday 27 April 
Drax Group PLCAGM
EP Global Opportunities Trust PLCAGM
Global Invacom Group LtdAGM
Hutchmed (China) LtdAGM
London Stock Exchange Group PLCAGM
McKay Securities PLCGM re Workspace offer
Nichols PLCAGM
Persimmon PLCAGM
Primary Health Properties PLCAGM
VH Global Sustainable Energy Opportunities PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
4 Sep 2020 14:13

Hutchison Chi-Med begins latest trial of fruquintinib

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, said on Friday that it has initiated 'FRESCO-2' - a phase 3 registration study of 'fruquintinib' for the treatment of patients with metastatic colorectal cancer (CRC) in the US, Europe and Japan.

Read more
3 Sep 2020 21:27

IN BRIEF: Hutchison China Initiates Phase II Trial Of HMPL-453

IN BRIEF: Hutchison China Initiates Phase II Trial Of HMPL-453

Read more
10 Aug 2020 11:04

IN BRIEF: Hutchison Chi-Med Plans Surufatnib Marketing Application

IN BRIEF: Hutchison Chi-Med Plans Surufatnib Marketing Application

Read more
30 Jul 2020 17:56

IN BRIEF: Hutchison China Interim Loss Widens Despite Revenue Growth

IN BRIEF: Hutchison China Interim Loss Widens Despite Revenue Growth

Read more
28 Jul 2020 19:48

IN BRIEF: Hutchison China Amends License Agreement With Eli Lilly

IN BRIEF: Hutchison China Amends License Agreement With Eli Lilly

Read more
24 Jul 2020 15:45

Hutchison Chi-Med begins phase 1 study of 'HMPL-306'

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, has initiated a phase 1 study of 'HMPL-306', it announced on Friday, in patients with hematological malignancies in China.

Read more
24 Jul 2020 14:33

Chi-Med Trials Dual Inhibitor For Hematological Cancer

Chi-Med Trials Dual Inhibitor For Hematological Cancer

Read more
23 Jul 2020 16:03

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
23 Jul 2020 16:02

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
25 Jun 2020 15:08

Hutchison China Gets USD100 Million From US Private Equity Firm

Hutchison China Gets USD100 Million From US Private Equity Firm

Read more
18 Jun 2020 16:46

IN BRIEF: Hutchison China Gets US FDA Fast Track For Cancer Drug

IN BRIEF: Hutchison China Gets US FDA Fast Track For Cancer Drug

Read more
18 Jun 2020 09:18

Hutchison Chi-Med gets FDA fast track approval for fruquintinib

(Sharecast News) - Hutchison China MediTech, trading as 'Chi-Med', announced on Thursday that the US Food and Drug Administration (FDA) has granted 'fast track designation' for the development of 'fruquintinib'.

Read more
9 Jun 2020 14:06

Hutchison Chi-Med venture to surrender unused land in Guangzhou

(Sharecast News) - Hutchison China MediTech, trading as 'Chi-Med', announced on Tuesday that Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company (HBYS) - its 50-50 joint venture with Guangzhou Baiyunshan Pharmaceutical Holdings - has agreed the planned return of its remaining 34 years land-use rights on its 30,000 square metre unused site in Tong He Town with the Guangzhou government.

Read more
9 Jun 2020 13:25

UK TRADING UPDATE SUMMARY: Venture Life Sees Order Boost For Sanitiser

UK TRADING UPDATE SUMMARY: Venture Life Sees Order Boost For Sanitiser

Read more
4 Jun 2020 13:19

UK TRADING UPDATE SUMMARY: Open Orphan Launches Covid Testing Service

UK TRADING UPDATE SUMMARY: Open Orphan Launches Covid Testing Service

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.